Clinical Trials Directory

Trials / Conditions / Richter's Transformation

Richter's Transformation

15 registered clinical trials studyying Richter's Transformation — 5 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingCD45BE-HSPC + CART-45 Cells
NCT07451054
University of PennsylvaniaPhase 1
RecruitingONO-4538 Study in Patients With Richter's Transformation
NCT06936943
Ono Pharmaceutical Co., Ltd.Phase 2
RecruitingPhase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter'
NCT06043674
Christine RyanPhase 2
RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P
NCT05294731
BeiGenePhase 1 / Phase 2
TerminatedStudy of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy
NCT04806035
TG Therapeutics, Inc.Phase 1
TerminatedStudy of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
NCT04305444
Zhejiang DTRM BiopharmaPhase 2
TerminatedStudy of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
NCT03778073
TG Therapeutics, Inc.Phase 1
TerminatedObinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requi
NCT03153514
German CLL Study GroupPhase 2
Active Not RecruitingA Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5
NCT03162536
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1 / Phase 2
TerminatedIbrutinib, Nivolumab and Blinatumomab in Richter Transformation
NCT03121534
M.D. Anderson Cancer CenterPhase 2
TerminatedPNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
NCT02378038
Sierra Oncology LLC - a GSK companyPhase 2
TerminatedSelinexor in Initial or Refractory and/or Relapsed Richter's Transformation
NCT02138786
Karyopharm Therapeutics IncPhase 2
RecruitingRegistry of the German CLL Study Group
NCT02863692
German CLL Study Group—
CompletedEfficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
NCT01217749
Pharmacyclics LLC.Phase 1 / Phase 2
CompletedOxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
NCT00472849
M.D. Anderson Cancer CenterPhase 1 / Phase 2